Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 12/20 | 0.69 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9980695 | 0.92 | SLC18A3 (0.71) | SLC18A3HSD11B1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9980657 | 0.89 | SLC18A3 (0.73) | SLC18A3HSD11B1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL15489134 | 0.83 | SLC18A3 (0.51) | SLC18A3HSD11B1 | |
| SCHEMBL9980736 | 0.83 | SLC18A3 (0.96) | SLC18A3HSD11B1 | |
| SCHEMBL9980749 | 0.82 | SLC18A3 (0.75) | SLC18A3HSD11B1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9981040 | 0.81 | SLC18A3 (1.00) | SLC18A3HSD11B1 | |
| SCHEMBL5476619 | 0.79 | HSD11B1 (0.84) | SLC18A3HSD11B1KMT2A | |
| SCHEMBL1720591 | 0.79 | HSD11B1 (0.84) | SLC18A3HSD11B1KMT2A | |
| SCHEMBL1720014 | 0.79 | HSD11B1 (1.00) | SLC18A3HSD11B1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL12031745 | 0.79 | SLC18A3 (0.93) | SLC18A3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658131-B2 | Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | SIGMAR1, TMEM97, OPRM1 | SLC18A3 248/4885HSD11B1 1775/4885LMNA 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.